The same prescription drug costs dramatically more in the United States than in Canada because the US is the only major country that allows pharmaceutical companies to set whatever prices the market will bear. A vial of insulin that runs about $300 in the US sells for roughly $35 in Canada. A Flovent inhaler priced at $355 stateside costs around $36 north of the border. These are not different drugs or inferior formulations — they are the same medications, made in the same factories, separated by a border and a fundamentally different approach to pricing. According to a 2024 RAND Corporation analysis, US drug prices are 2.78 times higher than the average across 33 other OECD nations. For brand-name drugs specifically, the gap widens to 4.22 times higher — and even after accounting for rebates and discounts, Americans still pay more than three times what people in comparable countries pay.
Per capita drug spending in the US is double that of Canada. The problem is not generics, which are actually 33% cheaper in the US than elsewhere. The problem is almost entirely brand-name medications, and the system that lets their manufacturers dictate terms. This article breaks down exactly how the US ended up here — from the absence of government price controls and aggressive patent manipulation to pay-for-delay deals and pharmaceutical lobbying. We will also look at recent developments that may finally be shifting the balance, including the first-ever Medicare drug price negotiations and the controversial most-favored-nation executive order signed in 2025. For anyone managing a chronic condition like dementia, where long-term medication costs can be financially devastating, understanding these dynamics is not academic — it is survival.
Table of Contents
- Why Do Identical Prescription Drugs Cost So Much More in the US Than Canada?
- How Patent Manipulation Keeps US Drug Prices Artificially High
- Pay-for-Delay Deals and Lobbying — The Hidden Machinery of High Prices
- What Medicare Drug Price Negotiation Actually Means for Your Prescriptions
- The Most-Favored-Nation Gamble and Its Risks
- What the US-Canada Price Gap Looks Like in Real Dollar Terms
- Where US Drug Pricing Goes From Here
- Conclusion
- Frequently Asked Questions
Why Do Identical Prescription Drugs Cost So Much More in the US Than Canada?
The core difference comes down to government negotiation. Canada’s Patented Medicine Prices Review Board, known as the PMPRB, caps drug prices by benchmarking them against prices in 11 other countries — and notably, the US is not one of those reference nations. The PMPRB’s updated guidelines, which took effect January 1, 2026, continue this approach, ensuring that Canadian prices reflect what the rest of the developed world considers reasonable. In the US, the opposite was true for decades. Under the 2003 noninterference clause, Medicare — the single largest drug purchaser in the country — was explicitly prohibited from negotiating prices with pharmaceutical companies. Consider what this meant in practice.
When a manufacturer set the price for a drug like Eliquis at $521 per month, Medicare had to pay it. There was no counteroffer, no leverage, no alternative. Canada, meanwhile, evaluated the same drug against international benchmarks and arrived at a fraction of that cost. The pricing gap is not a mystery of economics — it is the predictable result of one country negotiating and the other refusing to. The consequences fall hardest on people who take medications every day for years. Families managing dementia care often juggle multiple prescriptions alongside cognitive therapies, and the cumulative cost of brand-name drugs in the US can force impossible choices between medication adherence and basic living expenses. In Canada, those same prescriptions are a manageable line item, not a financial crisis.
How Patent Manipulation Keeps US Drug Prices Artificially High
Even when a drug’s original patent should have expired, pharmaceutical companies have become extraordinarily skilled at extending their monopolies through a practice known as evergreening. A 2025 analysis by the Commonwealth Fund found that on average, 143 patent applications are filed and 69 patents granted on each of the nation’s 12 top-selling drugs. More than half of those patents — 56% — are filed after the drug has already received FDA approval. These are not patents on new discoveries. They cover minor reformulations, delivery devices, dosing schedules, and manufacturing processes designed to block generic competition. The most egregious example is AbbVie’s Humira, the blockbuster anti-inflammatory drug. AbbVie filed 311 patent applications on Humira, with 90% of them coming after the initial approval.
The result was a monopoly that lasted 20 years and generated over $200 billion in revenue. Humira’s primary patent expired in 2016, but biosimilar competitors — which could have driven prices down substantially — were delayed until 2023. That seven-year gap between patent expiration and actual competition represents billions of dollars extracted from patients and insurance systems. However, it is important to understand that evergreening is not technically illegal. These patents pass through the same US Patent and Trademark Office process as any other filing, and courts have generally upheld them. Challenging this system requires legislative reform, not just regulatory enforcement. For patients, the practical consequence is that a drug they have been taking for a decade may still have no affordable generic alternative, even though the original science behind it is decades old. This is particularly relevant for neurological medications, where switching to an alternative is not always clinically straightforward.
Pay-for-Delay Deals and Lobbying — The Hidden Machinery of High Prices
Beyond patents, brand-name manufacturers have another tool for keeping generic competitors off the market: paying them not to compete. In pay-for-delay agreements, a brand manufacturer settles a patent dispute with a generic company by offering cash or other incentives in exchange for the generic maker agreeing to delay its market entry. According to Public Citizen, these arrangements cost Americans an estimated $36 billion per year. The generic company gets a guaranteed payout without the risk of a court battle, and the brand manufacturer gets to keep charging monopoly prices for years longer. These deals are propped up by an extraordinary lobbying apparatus. The pharmaceutical industry is the top lobbying spender in Washington, outpacing defense, oil and gas, and technology.
That spending is targeted and strategic — it aims to influence every piece of legislation that might introduce price controls, expand generic competition, or allow drug importation from countries like Canada. The result is a policy environment where even modest reforms take years to pass and often arrive with significant loopholes. For families dealing with dementia, the practical impact is that many cognitive health medications and related treatments remain expensive long after they should have faced generic competition. A drug that costs $500 a month in the US might have been available for $50 if a generic had entered the market on schedule. Instead, a backroom deal between two corporations extended the monopoly, and the patient absorbed the cost. This is not a conspiracy theory — it is a well-documented business practice that the Federal Trade Commission has repeatedly scrutinized but has limited tools to prevent.
What Medicare Drug Price Negotiation Actually Means for Your Prescriptions
For the first time in the program’s history, Medicare has negotiated prices directly with pharmaceutical manufacturers. Under the Inflation Reduction Act, ten high-cost drugs received negotiated prices that take effect in 2026, with discounts ranging from 38% to 79% off list prices. Eliquis, the blood thinner, drops from $521 to $231 per month — a 56% reduction. Jardiance, the diabetes medication, falls from $573 to $197 per month, a 66% cut. The projected savings are $6 billion for Medicare and $1.5 billion in out-of-pocket costs for beneficiaries in the first year alone. The tradeoff is scope. Ten drugs out of thousands is a starting point, not a solution.
The Inflation Reduction Act allows Medicare to negotiate prices on additional drugs in subsequent years, but the pace is deliberately slow, and the pharmaceutical industry is challenging the program’s constitutionality in court. For someone taking a medication that was not among the first ten selected, nothing changes in 2026. The average Part D enrollee taking one of the selected drugs will see cost-sharing drop by about 50%, which is meaningful — but it highlights how far the system still has to go. For dementia caregivers, the relevance depends on the specific medications involved. Some drugs prescribed alongside cognitive treatments for comorbid conditions like diabetes and cardiovascular disease are on the list. But many neurological drugs are not yet included. The negotiation program’s future expansion will determine whether it becomes a genuine price correction or remains a limited pilot. Either way, the fact that Medicare can now negotiate at all represents a structural change that was politically unthinkable five years ago.
The Most-Favored-Nation Gamble and Its Risks
In May 2025, former President Trump signed an executive order requiring drugmakers to match or beat the lowest price paid by countries like Canada, Germany, or France — a policy known as most-favored-nation pricing. In July 2025, the administration sent letters to leading pharmaceutical manufacturers outlining the required steps. The idea is straightforward: if Canada pays $35 for a vial of insulin, the US should pay something comparable, not $300. The risk, however, is that the policy could backfire in an unexpected direction. Rather than lowering US prices to match international levels, pharmaceutical companies may attempt to raise prices in other countries to narrow the gap. If a company can pressure smaller markets into accepting higher prices, the reference point shifts upward, and US consumers see less benefit than promised.
Canada is already hedging against this possibility — the PMPRB’s updated guidelines deliberately benchmark against 11 countries that exclude the US, creating a firewall against American pricing pressure pulling Canadian costs upward. There is also a legal and implementation question. Executive orders can be challenged in court and reversed by subsequent administrations. The pharmaceutical industry has the resources and motivation to delay or weaken most-favored-nation pricing through litigation, and previous attempts at similar policies have stalled. For patients counting on lower prices, the warning is to treat executive orders as signals of intent rather than guaranteed outcomes. Until a policy survives legal challenges and produces actual price changes at the pharmacy counter, it remains aspirational.
What the US-Canada Price Gap Looks Like in Real Dollar Terms
The abstract statistics become visceral when you look at specific medications side by side. Symbicort, a common asthma inhaler with 120 doses, costs approximately $331 in the US and $86 in Canada — a 74% difference for a drug that millions of people use daily. Rybelsus, the GLP-1 medication for diabetes, runs over $1,000 in the US and roughly $369 in Canada, a 73% gap. Viagra, at 12 tablets of 100mg, is approximately $733 stateside versus $127 in Canada, an 83% savings.
Cialis follows a similar pattern: about $600 in the US versus $132 in Canada, a 78% difference. These are not luxury purchases. For someone managing multiple chronic conditions — as many dementia patients do — the monthly drug bill in the US can easily exceed $1,000 before insurance, and even insured patients face significant copays and deductible obligations. The same prescriptions in Canada might total a few hundred dollars. When families are already stretched thin by the costs of memory care, home health aides, and medical appointments, the additional burden of inflated drug prices can be the factor that forces a care decision no one wanted to make.
Where US Drug Pricing Goes From Here
The next several years will determine whether the current wave of reforms amounts to a genuine correction or a temporary political gesture. Medicare’s negotiation program is set to expand to additional drugs annually, and the most-favored-nation policy, if implemented and sustained, would create downward pressure on the highest-priced medications. Canada’s decision to benchmark against countries that exclude the US is a signal that international markets are preparing to defend their own pricing structures against spillover effects from American policy shifts. The deeper question is whether the US political system can sustain pressure against an industry that spends more on lobbying than any other sector.
Every previous attempt at comprehensive drug pricing reform has been diluted, delayed, or defeated. The Inflation Reduction Act’s negotiation provisions survived because they were narrowly targeted and phased in gradually. Broader reforms — like allowing widespread importation from Canada or imposing across-the-board price caps — remain politically contested. For anyone paying American drug prices today, the honest assessment is that meaningful relief is beginning but far from complete, and vigilance about both policy developments and personal cost-management strategies remains essential.
Conclusion
The price gap between US and Canadian drugs is not a natural economic phenomenon — it is the product of deliberate policy choices, aggressive patent strategies, and an industry that has spent decades ensuring it can charge American patients more than anyone else on earth. The RAND data showing US prices at 2.78 times the OECD average, the 311 patent applications on a single drug, the $36 billion annual cost of pay-for-delay deals — these are not market forces at work. They are the architecture of a system designed to maximize revenue at the expense of patients.
For families navigating dementia care and brain health, the practical takeaway is to stay informed about which drugs are covered under Medicare’s new negotiation program, to ask providers about generic alternatives whenever possible, and to watch the implementation of most-favored-nation pricing with cautious optimism. The structural barriers to affordable medication in the US are real and deeply entrenched, but they are also, for the first time in decades, under genuine political pressure. The reforms now underway are incomplete, but they represent the first cracks in a system that has resisted change for a generation.
Frequently Asked Questions
Why are generic drugs cheaper in the US but brand-name drugs so much more expensive?
US generic drug prices are actually about 33% lower than in other countries because the US has a relatively competitive generic market. The problem is brand-name drugs, which average 4.22 times higher than in comparison nations. Patent manipulation and pay-for-delay deals keep generics off the market for brand-name drugs far longer than intended, so the brand-name premium persists for years or decades beyond what the original patent term would allow.
Can Americans legally buy prescription drugs from Canada?
The legal landscape is complicated. Federal law technically prohibits importing prescription drugs from other countries, but the FDA has generally exercised enforcement discretion and not pursued individual consumers ordering small quantities for personal use. Some states have pursued formal importation programs, but these face regulatory and legal hurdles. Always consult with your healthcare provider and verify the legitimacy of any cross-border pharmacy before purchasing.
How much will Medicare’s drug price negotiations save the average senior?
For the 10 drugs negotiated under the Inflation Reduction Act, average Part D enrollee cost-sharing is expected to drop by approximately 50% in 2026. Total projected savings are $6 billion for Medicare and $1.5 billion in out-of-pocket costs for beneficiaries. However, these savings only apply to the specific drugs selected for negotiation — if your medications are not on the list, your costs remain unchanged until the program expands.
What is the most-favored-nation drug pricing policy?
Signed as an executive order in May 2025, it requires pharmaceutical manufacturers to offer the US prices that match or beat the lowest prices paid by countries like Canada, Germany, or France. The risk is that drug companies may try to raise prices in other countries rather than lowering them in the US. Canada has responded by benchmarking its own price controls against countries that exclude the US, attempting to insulate itself from this pressure.
Why does it matter for dementia care specifically?
Dementia patients often take multiple medications over many years — not just for cognitive symptoms but for comorbid conditions like diabetes, cardiovascular disease, and mood disorders. The cumulative cost of brand-name prescriptions can be financially devastating for families already managing expensive long-term care. Understanding drug pricing helps caregivers advocate for generics, take advantage of negotiated prices, and make informed decisions about treatment options.
